A downtrend has been apparent in Veru Inc. (VERU) lately. While the stock has lost 5.2% over the past week, it could witness ...

A downtrend has been apparent in Veru Inc. (VERU) lately with too much selling pressure. The stock has declined 9.2% over the ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate ...

$VERU insiders have traded $VERU stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales. Here’s a ...

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development ...

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation ...

A downtrend has been apparent in Veru Inc. (VERU) lately. While the stock has lost 5.2% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...